RT Journal Article
SR Electronic
T1 Modeling COVID-19 vaccine efficacy and coverage towards herd-immunity in the Basque Country, Spain
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.07.12.21260390
DO 10.1101/2021.07.12.21260390
A1 Nico Stollenwerk
A1 Javier Mar
A1 Joseba Bidaurrazaga Van-Dierdonck
A1 Oliver Ibarrondo
A1 Carlo Estadilla
A1 Maíra Aguiar
YR 2021
UL http://medrxiv.org/content/early/2021/07/15/2021.07.12.21260390.abstract
AB Vaccines have measurable efficacies, obtained first from vaccine trials. However, vaccine efficacy is not a static measure upon licensing, and the long term population studies are very important to evaluate vaccine performance and impact. COVID-19 vaccines were developed in record time and although the extent of sterilizing immunity is still under evaluation, the currently licensed vaccines are extremely effective against severe disease, with vaccine efficacy significantly higher after the full immunization schedule. We investigate the impact of vaccines which have different efficacies after first dose and after the second dose administration schedule, eventually considering different efficacies against severe disease as opposed to overall infection. As a proof of concept, we model the vaccine performance of hospitalization reduction at the momentary scenario of the Basque Country, Spain, with population in a mixed vaccination setting, giving insights into the population coverage needed to achieve herd immunity in the current vaccination context.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Basque Government through the Mathematical Modeling Applied to Health Project, BERC 2018-2021 program and by Spanish Ministry of Sciences, Innovation and Universities - BCAM Severo Ochoa accreditation SEV-2017-0718. M. A. has received funding from the European Union's Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie grant agreement No 792494, during which part of the present work has been conceived and started to be developed.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:naAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData is available upon request.